Determining In Vitro Synergistic Activities of tigecycline with Several Other Antibiotics against Brucella melitensis Using Checkerboard and Time-Kill Assays

References

• Pappas G, Papadimitriou P, Akritidis N, Christou L, Tsianos EV. The new global map of human brucellosis. Lancet Infect Dis 2006; 6: 91–9.
   PubMed Web of Science ®Google Scholar
• Health Ministry of Turkish Republic, Basic Health Service Annual Report of 2004.
   Google Scholar
• Young EJ, Brucella species. In: Mandell GL, Bennett JE, eds. Principles and Practice of Infectious Diseases. 5th ed. New York: Churchill Livingstone, 2000: 2386–93.
   Google Scholar
• Pappas G, Solera J, Akritidis N, Tsianos E. New ap-proaches to the antibiotic treatment of brucellosis. Int J Antimi-crob Agents 2005; 26: 101–5.
   PubMed Web of Science ®Google Scholar
• Noskin GA. Tigecycline: a new glycylcycline for treatment of serious infections. Clin Infect Dis 2005 1; 41 Suppl 5: 03–314.
   Google Scholar
• Kenny GE, Cartwright FD. Susceptibilities of Mycoplasma hominis, M. pneumoniae, and Ureoplasma urealyticum to GAR-936, dalfopristin, dirithromycin, evernimicin, gatifloxacin,linezolid,moxifloxacin,quinupristin-dalfopristin,andtelithromycin compared to their susceptibilities to reference macrolides, tetracyclines, and quinolones. Antimicrob Agents Chemother 2001; 45: 2604–8.
   Google Scholar
• Wallace RJ Jr, Brown-Elliott BA, Crist CJ, Mann L, Wilson RW. Comparison of the in vitro activity of the glycylcycline tige-cycline (formerly GAR-936) with those of tetracycline, minocy-cline, and doxycycline against isolates of nontuberculous myco-bacteria. Antimicrob Agents Chemother 2002; 46: 3164–7.
   PubMedGoogle Scholar
• Corbel MJ. Microbiological aspects. In: Madkour MM, ed. Madkour's brucellosis. 2th ed. Berlin Heidelberg New York: Springer-Verlag. 2001: 51–64.
   Google Scholar
• Alton GG, Jones LM, Angus RD, Verger JM. Techniques for the brucellosis Laboratory. Paris: Institut National de la recherche Agronomique (INRA). 1988: 34–61.
   Google Scholar
• Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Sixteenth Infor-mational Supplement M100-S16. CLSI, Wayne, PA, USA, 2006.
   Google Scholar
• Orhan G, Bayram A, Zer Y, Balci I. Synergy tests by E-test and checkerboard methods of antimicrobial combinations against Brucella melitensis. J Clin Microbiol 2005; 43: 140–3.
   PubMed Web of Science ®Google Scholar
• Odds FC. Synergy, antagonism, and what the chequer-board puts between them. J Antimicrob Chemother 2003; 52:1.
   PubMed Web of Science ®Google Scholar
• Rubinstein E, Lang R, Shasha B et al. In vitro suscepti-bility of Brucella melitensis to antibiotics. Antimicrob Agents Chemother 1991; 35: 1925–7.
   PubMed Web of Science ®Google Scholar
• Petersen PJ, Jones CH, Bradford PA. In vitro antibac-terial activities of tigecycline and comparative agents by time-kill kinetic studies in fresh Mueller-Hinton broth. Diagn Microbiol In-fect Dis 2007; 59: 347–9.
   PubMed Web of Science ®Google Scholar
• Allen GP, Cha R, Rybak MJ. In vitro activities of quin-upristin-dalfopristin and cefepime, alone and in combination with various antimicrobials, against multidrug-resistant staphylococci and enterococci in an in vitro pharmacodynamic model. An-timicrob Agents Chemother 2002; 46: 2606–12.
   PubMed Web of Science ®Google Scholar
• Meagher AK, Ambrose PG, Grasela TH, Ellis-Grosse EJ. Pharmacokinetic/ pharmacodynamic profile for tigecycline-a new glycylcycline antimicrobial agent. Diagn Microbiol Infect Dis 2005; 52: 165–71.
   PubMed Web of Science ®Google Scholar
• Rodvold KA, Gotfried MH, Cwik M, Korth-Bradley JM, Dukart G, Ellis-Grosse EJ. Serum, tissue and body fluid concen-trations of tigecycline after a single 100 mg dose. J Antimicrob Chemother 2006; 58: 1221–9.
   PubMed Web of Science ®Google Scholar
• Ong CT, Babalola CP, Nightingale CH, Nicalou DP. Pen-etration, efflux and intracellular activity of tigecycline in human polymorphonuclear neutrophils (PMNs). J Antimicrob Chemother 2005; 56: 498–501.
   PubMed Web of Science ®Google Scholar
• Dizbay M, Kilic S, Hizel K, Arman D. Tigecycline: its po-tential for treatment of brucellosis. Scand J Infect Dis 2007; 39: 432–4.
   PubMed Web of Science ®Google Scholar
• Turan H, Arslan H, Azap OK, Serefhanoglu K, Uncu H. In vitro antibacterial activity of tigecycline in comparison with doxycycline, ciprofloxacin and rifampicin against Brucella spp. Int J Antimicrob Agents 2007; 30: 186–7.
   PubMed Web of Science ®Google Scholar
• Kilic D, Dizbay M, Cabadak H. In vitro activity of tigecy-cline, tetracycline and fluoroquinolones against Brucella meliten-sis. J Chemother 2008; 20: 33–7.
   PubMed Web of Science ®Google Scholar
• White RL, Burgess DS, Manduru M, Bosso JA. Compar-ison of three different in vitro methods of detecting synergy: time-kill, checkerboard, and E test. Antimicrob Agents Chemother 1996; 40: 1914–8.
   PubMed Web of Science ®Google Scholar
• Pappas G, Seitaridis S, Akritidis N, Tsianos E. Treatment of brucella spondylitis: lessons from an impossible meta-analysis and initial report of efficacy of a fluoroquinolone-containing reg-imen. Int J Antimicrob Agents 2004; 24: 502–7.
   PubMed Web of Science ®Google Scholar
• Arda B, Tuncel M, Yaimazhan T, Gökengin D, Gtirel 0. Efficacy of oral levofloxacin and dirithromycin alone in combi-nation with rifampicin in the treatment of experimental murine Brucella abortus infection. Int J Antimicrob Agents 2004; 23: 204–7.
   Google Scholar
• Solera J, Espinosa A, Martinez-Alfaro E, et al. Treatment of human brucellosis with doxycycline and gentamicin. Antimi-crob Agents Chemother 1997; 41: 80–4.
   PubMed Web of Science ®Google Scholar
• Ariza J, Bosilkovski M, Cascio A, et al. Perspectives for the treatment of brucellosis in the 21st century: The Ioannina recommendations. PLoS Med 2007; 12: 317.
   Google Scholar
• Petersen PJ, Labthavikul P, Jones CH, Bradford PA. In vitro antibacterial activities of tigecycline in combination with other antimicrobial agents determined by chequerboard and time-kill kinetic analysis. J Antimicrob Chemother 2006; 57: 573–6.
   PubMed Web of Science ®Google Scholar
• Chandrasekar PH, Crane LR, Bailey EJ. Comparison of the activity of antibiotic combinations in vitro with clinical out-come and resistance emergence in serious infection by Pseudomonas aeruginosa in non-neutropenic patients. J An-timicrob Chemother 1987; 19: 321–9.
   PubMed Web of Science ®Google Scholar